Arovella Therapeutics Limited (AU:ALA)
ASX:ALA
Top Page
Arovella Therapeutics Limited
(Sydney:ALA)
Select Model
Select Model
Rating:48Neutral
Price Target:
AU$0.09
▲(15.00% Upside)
Action:ReiteratedDate:04/11/26
The score is primarily held back by weak financial performance—ongoing losses and sustained cash burn—despite a low-debt balance sheet. Technicals provide some support with price above major moving averages, but mixed momentum (negative MACD and low RSI) tempers the outlook. Valuation is constrained by negative earnings (negative P/E) and no dividend yield data.
Positive Factors
Conservative balance sheet / low debt
Essentially no debt and a materially stronger equity base provide durable financial flexibility for an early-stage biotech. This reduces interest burden and short-term solvency risk, extending runway for R&D and enabling non-dilutive partnership or licensing options over months.
Negative Factors
Persistent operating losses and negative cash flow
The company remains in a heavy loss-making phase with sustained negative operating and free cash flow, meaning it is not self-funding. Over months this necessitates external funding, increasing dilution risk and constraining long-term strategic flexibility if losses persist.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative balance sheet / low debt
Essentially no debt and a materially stronger equity base provide durable financial flexibility for an early-stage biotech. This reduces interest burden and short-term solvency risk, extending runway for R&D and enabling non-dilutive partnership or licensing options over months.
Read all positive factors
Arovella Therapeutics Limited (ALA) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$112.42M
Dividend YieldN/A
Average Volume (3M)1.58M
Price to Earnings (P/E)―
Beta (1Y)1.72
Revenue Growth700.00%
EPS Growth26.88%
CountryAU
Employees27
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding1,208,783,700
10 Day Avg. Volume1,549,358
30 Day Avg. Volume1,578,675
Financial Highlights & Ratios
PEG Ratio0.54
Price to Book (P/B)5.47
Price to Sales (P/S)806.87
P/FCF Ratio-14.94
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Arovella Therapeutics Limited Business Overview & Revenue Model
Company Description
Arovella Therapeutics Limited, a biotechnology company, focuses on the development of therapies for the treatment of cancer and conditions that affect the central nervous system in Australia and internationally. Its product pipeline includes Zolpi...
How the Company Makes Money
null...
Arovella Therapeutics Limited Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
66
Positive
Cash Flow
22
Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | -3.30M | 136.00K | 17.00K | 405.90K | 295.81K | 257.35K |
| Gross Profit | -3.36M | 136.00K | -25.98K | -3.00M | 88.75K | 34.60K |
| EBITDA | -14.93M | -11.10M | -10.63M | -10.37M | -7.87M | -4.99M |
| Net Income | -7.93M | -7.51M | -8.75M | -10.18M | -8.62M | -5.05M |
Balance Sheet | ||||||
| Total Assets | 20.25M | 21.60M | 13.28M | 5.47M | 9.21M | 10.69M |
| Cash, Cash Equivalents and Short-Term Investments | 19.37M | 20.88M | 12.71M | 5.18M | 6.07M | 6.72M |
| Total Debt | 0.00 | 0.00 | 0.00 | 144.80K | 144.80K | 79.23K |
| Total Liabilities | 1.33M | 1.52M | 2.06M | 1.69M | 1.60M | 1.71M |
| Stockholders Equity | 18.92M | 20.08M | 11.23M | 3.78M | 7.62M | 8.98M |
Cash Flow | ||||||
| Free Cash Flow | -6.93M | -7.34M | -7.04M | -6.40M | -6.83M | -4.06M |
| Operating Cash Flow | -6.82M | -6.93M | -6.91M | -6.40M | -6.27M | -3.54M |
| Investing Cash Flow | -122.36K | -432.11K | -179.34K | 95.42K | -566.00K | -514.55K |
| Financing Cash Flow | 14.59M | 15.52M | 14.61M | 5.41M | 6.19M | 9.80M |
Arovella Therapeutics Limited Technical Analysis
Positive
0.08
Price Trends
0.08
Positive
0.08
Positive
0.09
Positive
Market Momentum
>-0.01
Negative
75.82
Negative
62.82
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:ALA, the sentiment is Positive. The current price of 0.08 is above the 20-day moving average (MA) of 0.07, below the 50-day MA of 0.08, and below the 200-day MA of 0.09, indicating a bullish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 75.82 is Negative, neither overbought nor oversold. The STOCH value of 62.82 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:ALA.
Arovella Therapeutics Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
57 Neutral | AU$39.28M | -25.86 | 10.35% | 2.81% | 0.65% | -9.90% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | AU$112.42M | -14.80 | -40.65% | ― | 700.00% | 26.88% | |
47 Neutral | AU$79.53M | -3.83 | -24.81% | ― | ― | 26.64% | |
41 Neutral | AU$97.88M | -2.12 | -30.19% | ― | ― | 63.46% | |
41 Neutral | AU$37.17M | -4.45 | -93.66% | ― | 7.65% | -19.13% | |
41 Neutral | AU$138.81M | -2.84 | 279.21% | ― | ― | 0.66% |
* Healthcare Sector Average
AU:ALA
Arovella Therapeutics Limited
0.09
0.01
16.25%
AU:ATX
Amplia Therapeutics
0.16
0.10
192.45%
AU:ATH
Alterity Therapeutics
0.01
0.00
0.00%
AU:PIQ
Proteomics International Laboratories Ltd.
0.23
-0.24
-52.13%
AU:EZZ
EZZ Life Science Holdings Ltd.
0.84
-0.58
-41.16%
AU:RCE
Recce Pharmaceuticals Ltd.
0.48
0.18
61.62%
Arovella Therapeutics Limited Corporate Events
Arovella Therapeutics Seeks ASX Quotation for 1.6 Million New Shares
Apr 10, 2026
Arovella Therapeutics has applied to the ASX for quotation of 1,600,000 new ordinary fully paid shares, with an issue date of 8 April 2026. The additional securities arise from the exercise or conversion of existing options or other convertible in...
Arovella issues 1.6m new shares and affirms regulatory compliance
Apr 10, 2026
Arovella Therapeutics has issued 1,600,000 new ordinary shares on 8 April 2026 and notified the market that this issuance was conducted without a disclosure document under the Corporations Act. The company confirmed it is up to date with its finan...
Arovella Weighs Validity of Requisitioned Meeting for Board Appointments
Apr 10, 2026
Arovella Therapeutics has received a purported shareholder notice under section 249D of the Corporations Act from The Trust Company (Australia) Limited SBF A/C, which holds more than 5% of its voting shares. The notice requests a general meeting w...
Arovella’s Armoured CLDN18.2 CAR-iNKT Cells Show Strong Activity Against Gastric and Pancreatic Cancer In Vitro
Apr 1, 2026
Arovella Therapeutics has demonstrated that its novel CLDN18.2-targeting CAR engineered into iNKT cells can effectively kill CLDN18.2-positive pancreatic and gastric cancer cells in vitro. The studies, conducted at the University of North Carolina...
Arovella Wins TGA Green Light to Run ALA-101 Cell Therapy Trial Under Streamlined CTN Pathway
Mar 15, 2026
Arovella Therapeutics has received confirmation from Australia’s Therapeutic Goods Administration that its planned Phase 1 trial of ALA-101, an allogeneic CD19-targeting CAR-iNKT cell therapy, can proceed under the Clinical Trial Notificatio...
Arovella Therapeutics Announces Departure of Director Gary Phillips
Feb 9, 2026
Arovella Therapeutics Limited has disclosed that director Gary Phillips ceased to be a director of the company on 9 February 2026. The filing notes that at the time of his departure, Phillips held indirect interests comprising 788,888 fully paid o...
Arovella reshapes board as CAR-iNKT cell therapy program advances
Feb 9, 2026
Arovella Therapeutics has announced the retirement of Interim Chair and Non-Executive Director Dr Elizabeth Stoner and Non-Executive Director Gary Phillips, both effective 9 February 2026. In response to these significant board changes, the compan...
Arovella Steps Up Investor Outreach With Euroz Hartleys Forum and Roadshow
Feb 5, 2026
Arovella Therapeutics announced that CEO and Managing Director Dr Michael Baker is presenting at the Euroz Hartleys 2026 Healthcare Forum in Perth and will conduct a non-deal investor roadshow across Perth, Sydney and Melbourne from 5–10 Feb...
Arovella Wins FDA IND Clearance as It Enters Clinical Stage With CAR-iNKT Cancer Therapy
Feb 4, 2026
Arovella Therapeutics has become a clinical‑stage company after the US Food and Drug Administration accepted its Investigational New Drug application for ALA-101, a CAR-iNKT cell therapy for patients with CD19-positive lymphoma and leukaemia...
Arovella Wins FDA IND Clearance for Lead Cell Therapy ALA-101
Jan 29, 2026
Arovella Therapeutics has received U.S. Food and Drug Administration acceptance of its investigational new drug application for ALA-101, clearing the way for first-in-human Phase 1 trials in patients with relapsed or refractory CD19-positive non-H...
Arovella Files IND for Lead CAR-iNKT Therapy as Cash Reserves Back 2026 Clinical Push
Jan 22, 2026
Arovella Therapeutics reported progress in the second quarter of FY26, highlighted by the filing of an Investigational New Drug application with the U.S. FDA for its lead allogeneic CAR-iNKT candidate ALA-101, selection of CRO SAPRO to run a first...
Arovella Therapeutics Names New Company Secretary and CFO to Support Growth
Jan 21, 2026
Arovella Therapeutics has appointed Lachie Mallia as Company Secretary and Chief Financial Officer, effective 22 January 2026, replacing fellow Bio101 Financial Advisory director Tim Luscombe, who previously held the roles. Mallia, a director at B...
Arovella to Release 936,303 Escrowed Shares Issued for Investor Relations Services
Jan 14, 2026
Arovella Therapeutics has announced that 936,303 ordinary shares, issued on 4 August 2025 as non-cash consideration for investor relations services, will be released from voluntary escrow on 31 January 2026. The move modestly increases the company...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.